War Room/DailyClout Pfizer Document Analysis

Are the COVID-19 Shots a Vaccine or a Gene Therapy?

PART TWO

This report builds upon Part One, found here: https://dailyclout.io/report-95-mrna-covid-19-shots-vaccines-or-gene-therapy-products-part-1/

AUTHORS:

David Shaw
Cassie Papillon
Dr Chris Flowers MD
Loree Britt

Was the Food and Drug Administration's (FDA's) Vaccine and Related Biological Products Advisory Committee (VRBPAC) the correct advisory committee to recommend that Emergency Use Authorizations (EUAs) be granted for Pfizer and Moderna's mRNA COVID-19 vaccines? Evidence shows that the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) should have been tasked with an advisory role rather than VRBPAC.

For the quarter ending June 30, 2020, Moderna stated that **the FDA considered its mRNA COVID-19 drug to be gene therapy and not a "vaccine."** Yet, the FDA, CDC, and public health agencies worldwide presented mRNA COVID-19 drugs to the public as "vaccines," not gene therapy. Additionally, a growing number of experts are evaluating what exactly is in the COVID-19 "vaccines." Their findings shine light onto whether this product is a "vaccine" or gene therapy and, more broadly, whether proper informed consent has been provided to consumers.

Why Did the FDA Choose VRBPAC to Review the Pfizer COVID-19 Product Instead of the Gene Therapies Committee?

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC), is the appropriate advisory committee to review and advise on the FDA on gene therapy products, such as the mRNA COVID-19 "vaccines." *The CTGTAC description of duties states that it* ***"…reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of*** human cells, human tissues***, gene transfer therapies***…which are intended for transplantation, implantation, infusion and transfer in the prevention and ***treatment of a broad spectrum of human diseases***..."[Emphasis added.] Since the FDA defined Moderna's COVID mRNA product as gene therapy, it clearly falls within CTGTAC's self-described duties.

Why Did the FDA Select VRBPAC, Not CTGTAC, As the mRNA COVID-19 Products' Advisory Committee?

Since the FDA knows the mRNA COVID-19 "vaccines" are actually gene therapy and has a gene therapies-specific advisory committee, one must question why the FDA selected VRBPAC, not CTGTAC, as the COVID-19 drug products' advisory committee. Given the seeming misassignment of advisory duties to VRBPAC, it appears the FDA did not act within its stated mission to protect public health as millions of Americans were injected with gene therapy products. Selecting an advisory committee with expertise in the drug technology platform being evaluated is a basic first step to protecting public health. Yet, the FDA did not do that; and the American public has since learned of health horrors resulting from what appears to be lack of appropriate advisement and oversight.

Consider the alarming presence of viral spike protein and vaccinal spike protein in the blood serum of patients with Long COVID syndrome: "Although official data state that vaccinal spike protein is harmless and remains at the site of infection [sic]**, several studies proposed spike protein toxicity and found it in blood circulation several months after the vaccination**." [Emphasis added.]
https://www.europeanreview.org/article/34685

Moreover, as reported in *The Telegraph*, "An article in *Nature* stunningly found that one in four who had Pfizer COVID jabs experienced (an) **unintended immune response**." The Cambridge scientists discovered, ***"…vaccines were not perfect and sometimes led to nonsense proteins being made instead of the desired Covid 'spike', which mimics infection and leads to antibody production (and) an immune system flare-up.***" [Emphasis added.]

Also, in South Korea, two pre-print studies address additional adverse events from the mRNA COVID shots: "The spectrum of non-fatal immune-related adverse events following COVID-19 vaccination" and "Hematologic abnormalities after COVID-19 vaccination**."**

If the correct FDA advisory committee oversaw the gene therapy mRNA COVID-19 drugs' creation and potential EUA recommendation, perhaps some of the crippling adverse events detected during the clinical trials would have raised more of an alarm *before* they were rolled out publicly.

08FEB24